Barclays Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
Tweet Send to a Friend
Barclays analyst Gena Wang reiterated an Overweight rating and $94.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


